多西他赛联合顺铂治疗转移性乳腺癌的临床观察

目的：观察多西他赛联合顺铂治疗转移性乳腺癌的疗效及不良反应。方法：选择我科2005年6月-2008年6月收治的31例转移性乳腺癌患者，给予多西他赛联合顺铂（TP方案）化疗，21d为1个周期，2周期后评价疗效。有效者给予6周期的化疗。结果：31例患者有效率51．6％，其中012例，PR14例。中位疾病进展时间8．6个月，中位生存时间19．2个月。主要不良反应为骨髓抑制及消化道反应和脱发。其中Ⅲ度以上白细胞减少的发生率26．0％。结论：多西他赛联合顺铂治疗转移性乳腺癌的疗效确切，不良反应可以耐受。

The clinical observation of combined therapy with docetaxel and cisplatin in treatment of metastatic breast cancer

Objective：To study the efficacy and side effects of concurrent docetaxel with cisplatin for metastatic breast cancer. Methods： To select 31 metastatic breast cancer patients 17 patients were treated by marcellomycin, ld patients were not treated by marcellomycin previously. All of them were treated with docetaxel and cisplatin combination regimen for two weeks followed by one week rest as one cycle, the clinical effect were evaluated after two cycles. Results： Of all the 31 patients ,2 eases were completely response and 14 cases were partially response, and the total effective rate was 51.6%. The progression of disease time（TFP） was 8.6 months,median survival time was 19.2 months . The main toxicity included the tolerable alimentary tract reaction, bone marrow depression and baldness, 26.0% patients developed degree Ⅲ myelosuppression. Conclusion：The combination of docetaxel and cisplatin treating the metastatic breast cancer patients is effective and with tolerated adverse effect.